Extract
Acusphere's AI-700 Pilot Study Exceeds Expectations.
WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ:ACUS) today announced that all six of its independent blinded readers were able to read a subset of ultrasound images from the pilot phase of the Phase 3 clinical program at sensitivity and specificity levels that exceeded the pre-specified clinical endpoint criteria for success in the pivotal trials for its l...
See the full content of this document
Sponsored links
